El interés en corto de AnaptysBio da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de AnaptysBio. Los datos de interés en corto se actualizan cada dos semanas.

AnaptysBio (NASDAQ:ANAB) Bolsa, Informe de interés en corto

ANAPTYSBIO INC

AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

ANAB

ANIK

ANNA

AREB

ASBP

CDLX

ELME

FAMI

HEPA

INTC

NOVA

PATH

SGBX

SNES

STGW

YOSH

Intel designa un nuevo CEO y sus acciones suben con fuerza en el premercado. Descubre qué otros valores destacan hoy.

Las acciones de Intel suben más del 10%; 20 acciones que se están moviendo en el premercado

ASST

CCLD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DWTX

HSDT

HUBC

LSTA

NEHC

NFLX

SEPN

STFS

USEG

Netflix sorprende con un aumento en suscriptores y mejores pronósticos. Descubre también los mayores ganadores y perdedores del premercado.

Acciones de Netflix se disparan alrededor del 15%; 20 acciones que se están moviendo en el premercado de EE.UU.

Long Ideas

Insider Trades

$FET

YUMC

Descubre las recientes compras de insiders en AnaptysBio, Forum Energy y Yum China, indicando posibles oportunidades de inversión.

Insider Trading: Compras en Yum China, AnaptysBio y Forum Energy Technologies

Across the recent three months, 5 analysts have shared their insights on AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.4, a high estimate of $90.00, and a low estimate of $38.00. Surpassing the previous average price target of $42.00, the current average has increased by 43.81%.
<img src="https://www.benzinga.com/files/images/story/2025/1753380018_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of AnaptysBio by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Martin Fan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AnaptysBio. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of AnaptysBio's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of AnaptysBio's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About AnaptysBio</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>A Deep Dive into AnaptysBio's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: AnaptysBio's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 286.84%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AnaptysBio's net margin excels beyond industry benchmarks, reaching -141.62%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -74.99%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): AnaptysBio's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -8.68%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: AnaptysBio's debt-to-equity ratio stands notably higher than the industry average, reaching 0.46. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For AnaptysBio's Future

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Overweight and raises the price target from $42 to $80.

Price Target

JP Morgan Maintains Overweight on AnaptysBio, Raises Price Target to $80

AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a>.
In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45757627/anaptys-announces-positive-rosnilimab-data-updated-through-six-months-in-robust-phase-2b-trial-in-" rel="noreferrer noopener">over six months</a>.
Furthermore, responses were then durable for at least two months off the drug.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42445688/anaptysbio-discontinues-investment-in-eczema-candidate-after-disappointing-data" rel="noreferrer noopener">AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data</a>
Rosnilimab was safe and well tolerated, particularly compared to standard-of-care biologics or JAKs.
All three doses (100mg Q4W, 400mg Q4W, 600mg Q2W) achieved statistically significant reductions in DAS-28 CRP and ACR20 at Week 12 versus placebo.
CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses by Week 14.
The company aims to complete its Phase 2 study for rosnilimab in ulcerative colitis/UC, with initial data expected in the fourth quarter of 2025.
As of the March 11, 2025&nbsp;data cutoff date, 83% were still in LDA at Week 34 across all doses. Of the remaining 17% of patients who did not sustain CDAI LDA at Week 34, most remained near the cutoff of CDAI=10, with a median CDAI of 13.
Rosnilimab demonstrated clinically meaningful improvements that deepened through Week 28 across multiple validated patient-reported outcomes, including the pain visual analog scale (VAS) and the health assessment questionnaire, or HAQ-Disability Index (DI), a self-reporting tool to measure function and disability.
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;Given the data showcase a positive holistic story for rosnilimab in RA, we are increasingly positive on upcoming UC data.&#8221;
Bodnar upgraded AnaptysBio from Neutral to Buy, raising the price target<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings" target="_blank" rel="noreferrer noopener"> from $22 to $38</a>.
HC Wainwright Highlights Competitor Datasets
Data using non-responder imputation (NRI) from Week 24 of the SELECT-CHOICE trial, which compared AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq vs Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Orencia in rheumatoid arthritis (RA), showed similar results for both drugs. These findings align with the results seen for the company&#8217;s rosnilimab at Week 28, even though about 29% of patients had previously been treated with JAK inhibitors.
In contrast, Eli Lilly And Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) now-discontinued PD-1 agonist peresolimab showed a drop in CDAI LDA rates—from 55% at Week 14 to 37% at Week 24. This is notably lower than the 53–63% range reported for rosnilimab at Week 28.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is also set to present early data for its PD-1 agonist at the upcoming EULAR conference, though its study is smaller than AnaptysBio&#8217;s.
Price Action: ANAB stock is down 12.1% at $20.66 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45769045/tariffs-ai-and-trade-war-apples-smartphone-growth-to-take-a-hit-experts-say" target="_blank" rel="noreferrer noopener">Tariffs, AI And Trade War: Apple&#8217;s Smartphone Growth To Take A Hit, Experts Say</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Upgrades

Health Care

General

ABBV

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday.
The Dow traded up 0.09% to 42,558.84 while the NASDAQ rose 0.31% to 19,459.23. The S&amp;P 500 also rose, gaining, 0.19% to 5,981.93.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45744658/jim-cramer-recommends-nvidia-over-very-cheap-semiconductor-stock">Jim Cramer Recommends Nvidia Over &#8216;Very Cheap&#8217; Semiconductor Stock</a>
Leading and Lagging Sectors Communication services shares jumped by 1.1% on Wednesday.
In trading on Wednesday, energy stocks fell by 1.7%.
Top Headline
The ISM services PMI dipped to 49.9 in May versus 51.6 in the previous month and also missing market estimates of 52.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) shares shot up 33% to $9.08 after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.</li>
<li>Shares of K Wave Media Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWM#NASDAQ">KWM</a>) got a boost, surging 115% to $4.1303 after the company announced it signed a $500 million securities purchase agreement to advance a bitcoin-focused treasury strategy.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares were also up, gaining 61% to $0.4466 after the company announced it was granted FDA Breakthrough Therapy Designation status for Iopofosine I-131.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) shares dropped 17% to $15.78 following first-quarter results.</li>
<li>Shares of AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) were down 10% to $21.19 after the company announced Rosnilimab data from its six-month Phase 2b trial for rheumatoid arthritis (RA).</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) was down, falling 8% to $89.00 after the company posted first-quarter results.</li>
</ul>
Commodities In commodity news, oil traded down 1.2% to $62.64 while gold traded up 0.7% at $3,398.90.
Silver traded down 0.2% to $34.56 on Wednesday, while copper rose 0.8% to $4.8710.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.55%, while Spain's IBEX 35 Index fell 0.14%. London's FTSE 100 rose 0.20%, Germany's DAX 40 gained 0.76% and France's CAC 40 rose 0.64% during the session.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei gaining 0.80%, Hong Kong's Hang Seng Index jumping 0.60%, China's Shanghai Composite gaining 0.42% and India's BSE Sensex gaining 0.32%.
Economics
<ul class="wp-block-list">
<li>The EIA said crude oil inventories in the U.S. declined by 4.304 million barrels in the week ended May 30, compared to market estimates of a 0.9 million barrel fall.</li>
<li>The ISM services PMI dipped to 49.9 in May versus 51.6 in the previous month and also missing market estimates of 52.</li>
<li>The S&amp;P Global composite PMI was revised higher to 53.0 in May compared to a preliminary reading of 52.1 and versus April's reading of 50.6.</li>
<li>U.S. private business added 37K workers to their payrolls during May versus a revised 60K gain in the previous month.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/45771113/this-apple-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-wednesday-2">This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

ASAN

CLRB

DLTR

YEXT

Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Emily Bodnar upgraded the rating for AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Neutral to Buy and raised the price target from $22 to $38. AnaptysBio shares closed at $23.52 on Tuesday. <a href="https://www.benzinga.com/quote/ANAB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst David Anderson upgraded Cactus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) from Equal-Weight to Overweight and raised the price target from $51 to $54. Cactus shares closed at $44.11 on Tuesday. <a href="https://www.benzinga.com/quote/WHD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Cenk Orcan upgraded the rating for Embraer S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) from Hold to Buy and raises the price target from $45 to $57. Embraer shares closed at $45.99 on Tuesday. <a href="https://www.benzinga.com/quote/ERJ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst David Lebowitz upgraded Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sell to Neutral and raised the price target from $83 to $129. Blueprint Medicines shares closed at $127.60 on Tuesday. <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Karl Keirstead upgraded Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Buy and raised the price target from $210 to $265. Snowflake shares closed at $209.18 on Tuesday. <a href="https://www.benzinga.com/quote/snow/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SNOW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SNOW/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-1024x599.png" alt="" class="wp-image-938280" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

BPMC

Embraer-Empresa Brasileira De Aeronautica

SNOW

This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

HC Wainwright &amp; Co. analyst Emily Bodnar upgrades AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Neutral to Buy and raises the price target from $22 to $38.

HC Wainwright & Co. Upgrades AnaptysBio to Buy, Raises Price Target to $38

WIIM

AnaptysBio shares are trading higher after the company announced Rosnilimab data from its six-month Phase 2b trial for rheumatoid arthritis (RA).

Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month​ blinded treatment periodFavorable safety and tolerability, particularly when compared to
<ul>
<li>Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month​ blinded treatment period</li>
<li>Favorable safety and tolerability, particularly when compared to standard of care biologics or JAKs</li>
<li>Max response rates have not yet been observed; strict continuation criteria at three months in this Phase 2b trial excluded many patients who either achieved or were trending toward LDA and ACR50
<ul>
<li>Durable responses for at least two months off drug, with potential for extended dosing intervals (e.g. Q8W) in the maintenance setting</li>
</ul>
</li>
</ul>

Anaptys Reports Rosnilimab Data Updated Through Six Months In Phase 2b Trial In RA

Across the recent three months, 5 analysts have shared their insights on AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $49.6, a high estimate of $90.00, and a low estimate of $22.00. Observing a 21.57% increase, the current average has risen from the previous average price target of $40.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1748462436_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of AnaptysBio among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Martin Fan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AnaptysBio. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of AnaptysBio's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of AnaptysBio's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind AnaptysBio</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>A Deep Dive into AnaptysBio's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: AnaptysBio's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 286.84%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AnaptysBio's net margin is impressive, surpassing industry averages. With a net margin of -141.62%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AnaptysBio's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -74.99%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): AnaptysBio's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.68%, the company may face hurdles in achieving optimal financial returns.
Debt Management: AnaptysBio's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.46, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday.
Shares of HEICO Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) rose sharply during Wednesday's session following <a href="https://www.benzinga.com/quote/HEI/earnings">better-than-expected quarterly results.</a>
Heico reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $1.03 per share. The company reported quarterly sales of $1.10 billion which beat the analyst consensus estimate of $1.06 billion.
HEICO shares surged 7.2% to $293.77 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>LiveWire Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NASDAQ">LVWR</a>) surged 30% to $3.33 after jumping 153% on Tuesday.</li>
<li>Monro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) gained 29% to $16.47 after the company reported a fourth-quarter revenue beat and approved a first-quarter cash dividend of $0.28 per share. Additionally, the company announced it has conducted a store portfolio review and has identified 145 underperforming locations for closure.</li>
<li>Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) shares jumped 26.8% to $97.88 after the company reported better-than-expected quarterly financial results.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) gained 26.3% to $10.77 after the company announced it is looking to wind down operations and is exploring asset sales.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) rose 23.5% to $8.49 after the company completed a round of raising capital, which included a $250 million investment from Toyota Motor.</li>
<li>CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) jumped 16.3% to $2.4700.</li>
<li>Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) gained 15.3% to $36.25 after the company reported better-than-expected first-quarter financial results and raised its FY26 guidance.</li>
<li>Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) rose 13.7% to $172.50 after JP Morgan upgraded the stock from Underweight to Neutral.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) gained 10.7% to $22.29. Guggenheim analyst Yatin Suneja maintained AnaptysBio with a Buy and raised the price target from $54 to $90.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) shares rose 10.6% to $6.59.</li>
<li>Conduent Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNDT#NASDAQ">CNDT</a>) gained 6.9% to $2.2450.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) rose 6.5% to $23.24.</li>
<li>Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) gained 5% to $18.39 following strong quarterly sales.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

CNDT

CPRI

CTMX

EYPT

ITOS

JOBY

LVWR

MNRO

Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday

Guggenheim analyst Yatin Suneja maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and raises the price target from $54 to $90.

Guggenheim Maintains Buy on AnaptysBio, Raises Price Target to $90

AnaptysBio To Reveal Updated Data From Phase 2b Trial of Rosnilimab, A PD-1 Depleter And Agonist, For Rheumatoid Arthritis On June 3, 2025

Analysts' ratings for AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for AnaptysBio, presenting an average target of $41.5, a high estimate of $54.00, and a low estimate of $22.00. Observing a 8.27% increase, the current average has risen from the previous average price target of $38.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1746561656_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive AnaptysBio is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Martin Fan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AnaptysBio. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for AnaptysBio's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AnaptysBio's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AnaptysBio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About AnaptysBio</h2>
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
<h3>Understanding the Numbers: AnaptysBio's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: AnaptysBio's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 378.77%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: AnaptysBio's net margin excels beyond industry benchmarks, reaching -50.53%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): AnaptysBio's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -28.07%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -4.46%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.23, AnaptysBio adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For AnaptysBio

Guggenheim analyst Yatin Suneja maintains AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Buy and raises the price target from $52 to $54.

Guggenheim Maintains Buy on AnaptysBio, Raises Price Target to $54

AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.25) by 2.4 percent. This is a 21.95 percent increase over losses of $(1.64) per share from the same period last year. The company reported quarterly sales of $27.77 million which beat the analyst consensus estimate of $15.27 million by 81.82 percent. This is a 286.84 percent increase over sales of $7.18 million the same period last year.

Earnings Beats

Earnings Misses

AnaptysBio Q1 EPS $(1.28) Misses $(1.25) Estimate, Sales $27.77M Beat $15.27M Estimate

Wedbush analyst Martin Fan reiterates AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) with a Outperform and maintains $40 price target.

Reiteration

Wedbush Reiterates Outperform on AnaptysBio, Maintains $40 Price Target

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 350 points on Monday.
The Dow traded up 1.35% to 42,551.10 while the NASDAQ climbed 2.08% to 18,119.66. The S&amp;P 500 also rose, gaining, 1.66% to 5,761.78.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44454777/top-3-risk-off-stocks-that-may-explode-this-month-2">Top 3 Risk Off Stocks That May Explode This Month</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 3.2% on Monday.
In trading on Monday, health care shares gained by just 0.4%.
Top Headline
The S&amp;P Global US Composite PMI climbed to 53.5 in March compared to February's reading of 51.6, signalling the strongest growth since December 2024.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares shot up 11% to $18.91 after the company announced a $75 million share buyback program.</li>
<li>Shares of The AZEK Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>)got a boost, surging 14% to $47.23 amid an announcement that James Hardie will acquire the company for $8.75 billion.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares were also up, gaining 29% to $0.1422 after the company announced a strategic initiative to develop and deploy an advanced artificial intelligent cloud infrastructure in Malaysia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares dropped 86% to $0.7049 after the company announced the pricing of $12.0 million registered direct offering.</li>
<li>Shares of 23andMe Holding Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) were down 50% to $0.8901 after the company announced it has initiated voluntary Chapter 11 bankruptcy to pursue a strategic sale and secured $35M in DIP financing.</li>
<li>Unity Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) was down, falling 35% to $1.1867 after the company reported topline results from the ASPIRE Phase 2b study in diabetic macular edema.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $68.94 while gold traded up 0.2% at $3,027.80.
Silver traded up 0.5% to $33.660 on Monday, while copper rose 0.2% to $5.1260.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.15%, Germany's DAX 40 rose 0.28% and France's CAC 40 rose 0.09%. Spain's IBEX 35 Index rose 0.13%, while London's FTSE 100 gained 0.12%.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 falling 0.18%, China's Shanghai Composite Index rising 0.15%, Hong Kong's Hang Seng Index gaining 0.91% and India's BSE Sensex gaining 1.40%.
Economics
<ul>
<li>The Chicago Fed National Activity Index rose to 0.18 in February versus a reading of -0.08 in January.</li>
<li>The S&amp;P Global services PMI climbed to 54.3 in March from 51 in February.</li>
<li>The S&amp;P Global US Manufacturing PMI declined to 49.8 in March versus 52.7 in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44456813/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

AZEK

LUNR

WLGS

Crude Oil Gains 1%; US Composite PMI Surges In March

AnaptysBio shares are trading higher after the company announced a $75 million share buyback program.

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Monday.
Shares of Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) rose sharply during Monday's session <a href="https://www.benzinga.com/quote/LUNR/earnings">following fourth-quarter results</a>.
Intuitive Machines reported fourth-quarter revenue of $54.66 million, missing analyst estimates of $55.77 million, according to Benzinga Pro. Total revenue was up 79% on a year-over-year basis. The company said it ended the quarter with a record backlog of $328.3 million, up 22% year-over-year.
Intuitive Machines shares jumped 17.2% to $8.29 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Northern Dynasty Minerals Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) shares jumped 23% to $1.0957.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares jumped 20.8% to $20.63 after the company announced a $75 million share buyback program.</li>
<li>The AZEK Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) gained 18.3% to $48.96 amid an announcement that James Hardie will acquire the company for $8.75 billion.</li>
<li>Montauk Renewables, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) gained 15% to $2.5101.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) rose 12.5% to $25.06.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) gained 10.4% to $38.19.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) gained 10.3% to $29.97 after the company announced it is engaging with the US Nuclear Regulatory Commission regarding a pre-application for its combined license application of the aurora powerhouse at Idaho National Laboratory.</li>
<li>Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) rose 10.2% to $56.60.</li>
<li>Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) rose 9.4% to $175.34.</li>
<li>Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) surged 9.3% to $74.61 after Raymond James upgraded its rating on the stock from Outperform to Strong Buy despite lowering the price target from $110 to $91.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) gained 8.8% to $9.10. D-Wave Quantum filed for offering of 5 million common shares by selling stockholder.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) gained 8% to $47.90.</li>
<li>Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) climbed 7.9% to $71.87. Raymond James analyst Simon Leopold upgraded Lumentum from Outperform to Strong Buy and lowered the price target from $96 to $82.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 7.9% to $268.59.</li>
<li>Diginex Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) rose 7.6% to $118.37.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) gained 6.9% to $258.90. RH will report financial results for the fourth quarter and fiscal year 2024 ended Feb. 1, 2025, on Wednesday, April 2, 2025.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44456813/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields</a> Photo: Shutterstock</li>
</ul>

COHR

DGNX

HOOD

IONQ

LITE

LMND

MNTK

OKLO

QBTS

ROOT

TSLA

Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday

Buybacks

Anaptys Announces $75M Share Buyback Program

Press Releases

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Anaptys Announces Participation in March Investor Conferences

Anaptys Announces Stock Repurchase Plan

Management

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Comments

AnaptysBio

Interés en corto

AnaptysBio (NASDAQ:ANAB) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL